Summit Therapeutics plc Summit Therapeutics Plc : Miscellaneous
November 16 2017 - 2:00AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit" or the "Company")
SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER
Oxford, UK, 16 November 2017- Summit Therapeutics plc (NASDAQ: SMMT,
AIM: SUMM) the drug discovery and development company advancing
therapies for Duchenne muscular dystrophy and Clostridium difficile
infection, announces the appointment of Panmure Gordon as joint broker
with immediate effect to act alongside N+1 Singer.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for indications for
which there are no existing or only inadequate therapies. Summit is
conducting clinical programmes focused on the genetic disease Duchenne
muscular dystrophy and the infectious disease C. difficile infection.
Further information is available at www.summitplc.com and Summit can be
followed on Twitter (@summitplc).
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Pamure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
MacDougall Biomedical Communications (US) Tel: +1 781 235 3060
Karen Sharma ksharma@macbiocom.com
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / summit@consilium-comms.com
Jessica Hodgson / Philippa Gardner
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
November 16, 2017 02:00 ET (07:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2023 to Apr 2024